retatrutide triple agonist obesity trial Severe Shows 30% Weight Loss 🚨 Retatrutide TRIUMPH-1 Phase 3

The REDEFINE 1 Phase 3 trial demonstrated 20.4% mean weight loss at 68 weeks in 3,417 participants, and Novo Nordisk has filed an NDA with the FDA

Brand-Name vs Compounded GLP-1: A 2026 Decision Framework Patients in 2026 have three realistic supply paths: insurance-covered brand-name (Wegovy, Zepbound, Ozempic, Mounjaro), cash-pay brand-name via manufacturer self-pay (Novo NovoCare, Lilly LillyDirect), and cash-pay compounded semaglutide or tirzepatide through US-licensed compounding pharmacies

This peptide is frequently researched for its role in copper-peptide signalling, extracellular matrix activity, collagen-related pathways, and cellular-repair mechanisms

As of this writing, the drug has not received regulatory approval in the US, UK, EU, or anywhere else in the world, for that matter